Last reviewed · How we verify

NCT05264324

Maximal Exercise Capacity at 2500 m of High Altitude

Completed NA Last updated 11 May 2022
What this trial tests

NA trial testing Maximal Exercise Capacity in High Altitude Pulmonary Hypertension in 28 participants. Completed in 15 April 2022.

Timeline
20 October 2021
Primary endpoint
15 April 2022
15 April 2022

Quick facts

Lead sponsorUniversity of Zurich
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeprevention
Enrollment28
Start date20 October 2021
Primary completion15 April 2022
Estimated completion15 April 2022
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

University of Zurich

Who can join

18 and older, any sex, with High Altitude Pulmonary Hypertension or Maximal Exercise Capacity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The impact of hypoxia on maximal work rate during incremental ramp exercise within 3-6 hours after arriving at 2500m of high altitude in patients with precapillary pulmonary hypertension

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for High Altitude Pulmonary Hypertension

Currently open trials in the same condition.

Other University of Zurich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05264324.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing